<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776696</url>
  </required_header>
  <id_info>
    <org_study_id>rmc082315ctil</org_study_id>
    <nct_id>NCT02776696</nct_id>
  </id_info>
  <brief_title>Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2</brief_title>
  <official_title>Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare two closed-loop strategies in terms of glycemic
      control in Type 1 Diabetes during a camp setting.

      The proposed study is a three-segment feasibility study. One segment is a proof of concept
      study (with two parts) conducted as in-patient clinic study ,the second segment is two-arms,
      cross-over, randomized and single-center and the third segment is four-arms, parallel,
      randomized and single-center, in diabetes camp study in subjects with type 1 diabetes on
      insulin pump therapy.

      Segment 1 will be divided into two parts: part 1 is a single arm pilot study aim to asses
      logistical and safety issues in 12 patients and part 2 is a randomized cross over study aim
      to evaluate glucose performance using closed-loop control. Part 2-is a randomized cross-over
      (two arms) in-patient study: A total of 12 patients will participate in this part of the
      study. Following the run-in period subjects will be randomized to participate in two periods
      of closed-loop treatment, each period will last 36 hours in hospital setting. During the
      first period, glycemic control will be controlled by the Hybrid closed-loop system and during
      the second period by Hybrid Logic closed-loop system. The sequence of treatment first period
      HCL therapy than AHCL or vice versa will be randomly assigned.

      Segment 2 is a randomized cross-over (two arms) Camp Study including up to 30 patients.
      Following the run-in period subjects will be randomized to participate in two periods of
      closed-loop treatment, each period will last 2days in a camp setting, the total duration of
      the camp will be up to 6 days. In one period, glycemic control will be controlled by the
      Hybrid closed-loop system and another period by Hybrid Logic closed-loop system. The sequence
      of treatment first period HCL therapy than AHCL or vice versa will be randomly assigned.

      Segment 3 is a randomized, parallel (four arm) Camp Study including up to 80 patients.
      Following the run-in period subjects will be randomized to participate in one of 4
      intervention arms of closed-loop treatment in camp settings. The duration of the camp will be
      12 days in which glycemic control will be controlled by one of 4 versions of closed-loop
      system: Hybrid Closed Loop (HCL) or one of 3 versions of Advanced Hybrid Closed Loop (AHCL).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>segment 1 part 1 is a sigle arm study, segment 1 part 2 is a is a crossover study, segment 2 is a randomized crossover study and segment 3 is a parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of glucose sensor readings within 70 to 180 mg/dl</measure>
    <time_frame>Day 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of glucose sensor readings below 70 mg/dl</measure>
    <time_frame>Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose sensor readings below 70 mg/dl</measure>
    <time_frame>Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of glucose sensor readings above 180 mg/dl</measure>
    <time_frame>Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose sensor readings above 180 mg/dl</measure>
    <time_frame>Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of glucose sensor readings</measure>
    <time_frame>Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Deviation of glucose sensor readings</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in glucose range of 70-180 mg/dl during day time (6am-12am)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in glucose range of 70-180 mg/dl during night time (12am-6am)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of glucose sensor readings above 250 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of glucose sensor readings above 300 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose sensor readings above 250 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose sensor readings above 300 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of glucose sensor readings below 50 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of glucose sensor readings below 60 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose sensor readings below 50 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose sensor readings below 60 mg/dL</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time in Closed Loop</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensor mean absolute relative difference (MARD)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total insulin dose</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Device Events (SADE)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated Adverse Device Effects (UADE)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Hypoglycemia</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Diabetic Ketoacidosis (DKA)</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closed-loop acceptance questionnaire</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>user interface evaluation</measure>
    <time_frame>Last Day of Intervention ( day 21)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Advanced HybridClosed Loop System (AHCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hybrid Closed Loop System (HCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:
36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Advanced Hybrid Closed Loop System</intervention_name>
    <arm_group_label>Advanced HybridClosed Loop System (AHCL)</arm_group_label>
    <other_name>AHCL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Closed Loop System</intervention_name>
    <arm_group_label>Hybrid Closed Loop System (HCL)</arm_group_label>
    <other_name>HCL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes duration &gt; 1 year since diagnosis

          -  Pump therapy for at least 6 months and experience with sensor use

          -  Age 12-25 years

          -  7&gt;HbA1c &lt;10.0 at time of screening visit, &lt;10.0 at segment 3

          -  Willing to follow study instructions

          -  Willing to perform â‰¥ 3 finger stick blood glucose measurements daily

          -  Willing to perform required sensor calibrations

          -  Patient capable of reading and understand instructions in English

        Exclusion Criteria:

          -  Subject is unable to tolerate tape adhesive in the area of sensor placement

          -  Subject has any unresolved adverse skin condition in the area of sensor or device
             placement

          -  Subject is actively participating in an investigational study (drug or device) wherein
             they have received treatment from an investigational study (drug or device) in the
             last 2 weeks

          -  Subject has a positive pregnancy screening test

          -  Subject is female, sexually active without the use of contraception, and plans/able to
             become pregnant during the course of the study and is not using an acceptable method
             of contraception

          -  Subject has had a hypoglycemic seizure within the past 6 months prior to screening
             visit

          -  Subject has had hypoglycemia resulting in loss of consciousness within the past 6
             months prior to screening visit

          -  Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months
             prior to screening visit

          -  Subject has a history of a seizure disorder

          -  Subject has central nervous system or cardiac disorder resulting in syncope

          -  Subject has a history of myocardial infarction, unstable angina, coronary artery
             bypass surgery, coronary artery stenting, transient ischemic attack (TIA),
             cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm
             disturbances or thromboembolic disease

          -  Subjects with hematocrit lower than the normal reference range per local lab testing

          -  Subjects with a history or findings on screening electrocardiogram of any cardiac
             arrhythmia

          -  Subjects with a history of adrenal insufficiency

          -  Subjects with history of migraines that have occurred at least 2 times in the last 3
             months prior to enrollment

          -  Any disease or condition that may influence the HbA1c testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Closed Loop</keyword>
  <keyword>Artificial Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

